NASDAQ: $CGEM A Significant Milestone for Targeted Therapy Recent clinical data has brought a wave of optimism for patients battling non-small cell lung cancer (NSCLC). According to recent reports, the combination of zipalertinib and standard chemotherapy has successfully met its primary endpoint in a planned interim analysis, demonstrating a statistically significant improvement in progression-free survival…